1432509-23-3

Basic information

• Product Name: methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate
• Synonyms: methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate
• CAS NO: 1432509-23-3
• Molecular Weight: 440.337
• Mol File: 1432509-23-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate(1432509-23-3)
• EPA Substance Registry System: methyl 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)benzoate(1432509-23-3)

Safety Data

• Hazardous Substances Data: 1432509-23-3(Hazardous Substances Data)

Upstream product

• 126-81-8 dimedone 
• 40887-80-7 3-bromophenylhydrazine 

Downstream Products

• 1432508-14-9 4-((7-bromo-2,2-dimethyl-4-oxo-1,2,3,4-tetrahydrocarbazol-9-yl)methyl)-N-hydroxybenzamide 

Relevant articles and documents

HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF

The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease.